Insights into the Pharmacological Activity of the Imidazo−Pyrazole Scaffold

Abstract

AbstractIn previous studies, we synthesized different imidazo−pyrazoles 1 and 2 with interesting anticancer, anti‐angiogenic and anti‐inflammatory activities. To further extend the structure‐activity relationships of imidazo−pyrazole scaffold and to identify novel antiproliferative/anti‐inflammatory agents potentially active with multi‐target mechanisms, a library of compounds 3–5 has been designed and synthesized. The chemical modifications characterizing the novel derivatives include: i) decoration of the catechol ring with groups with different electronic, steric and lipophilic properties (compounds 3); ii) insertion of a methyl group on C‐6 of imidazo−pyrazole scaffold (compounds 4); iii) shift of the acylhydrazonic substituent from position 7 to 6 of the imidazo−pyrazole substructure (compounds 5). All synthesized compounds were tested against a panel of cancer and normal cell lines. Derivatives 3 a, 3 e, 4 c, 5 g and 5 h showed IC50 values in the low micromolar range against selected tumor cell lines and proved to have antioxidant properties, being able to inhibit ROS production in human platelet. In silico calculation predicted favourable drug‐like and pharmacokinetic properties for the most promising compounds. Furthermore, molecular docking and molecular dynamic simulations suggested the ability of most active derivative 3 e to interact with colchicine binding site in the polymeric tubulin α/tubulin β/stathmin4 complex.